Novel strategies for microdose studies using non-radiolabeled compounds.

[1]  C. Gui,et al.  Development of a Cell-Based High-Throughput Assay to Screen for Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 , 2010, Current chemical genomics.

[2]  D. J. Graham,et al.  The metabolism and pharmacokinetics of nicardipine hydrochloride in man. , 1985, British journal of clinical pharmacology.

[3]  Kazuya Maeda,et al.  Web-Based Database as a Tool to Examine Drug–Drug Interactions Involving Transporters , 2010 .

[4]  Y. Sugiyama,et al.  Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions. , 2010, Trends in pharmacological sciences.

[5]  Jürgen Brockmöller,et al.  Clinical Consequences of Cytochrome P450 2C9 Polymorphisms , 2005, Clinical pharmacology and therapeutics.

[6]  Y. Sugiyama,et al.  Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs , 2009, Expert opinion on drug metabolism & toxicology.

[7]  R. Colin Garner,et al.  The utility of microdosing over the past 5 years , 2008, Expert opinion on drug metabolism & toxicology.

[8]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[9]  R. C. Garner,et al.  Microdose Pharmacokinetics of IDX 899 and IDX 989 , Candidate HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors , Following Oral and Intravenous Administration in Healthy Male Subjects , 2009 .

[10]  S. Vavricka,et al.  Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver , 2002, Hepatology.

[11]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[12]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[13]  Y. Sugiyama,et al.  Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  Kazuya Maeda,et al.  Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans , 2008, Drug Metabolism and Disposition.

[15]  U. Fuhr,et al.  Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the “Cocktail” Approach , 2007, Clinical pharmacology and therapeutics.

[16]  Y Kumagai,et al.  Microdose study of a P‐glycoprotein substrate, fexofenadine, using a non‐radioisotope‐labelled drug and LC/MS/MS , 2010, Journal of clinical pharmacy and therapeutics.

[17]  Ulf Norinder,et al.  Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs , 2009, Pharmaceutical Research.

[18]  Kazuya Maeda,et al.  CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS , 2005, Drug Metabolism and Disposition.

[19]  A. D. Rodrigues,et al.  Enzyme- and transporter-based drug-drug Interaction , 2010 .

[20]  J. Nezu,et al.  Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human , 2004, Journal of Pharmacology and Experimental Therapeutics.

[21]  Yuichi Sugiyama,et al.  Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma. , 2009, Drug metabolism and pharmacokinetics.

[22]  Koujirou Yamamoto,et al.  Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. , 2005, Biological & pharmaceutical bulletin.

[23]  R. C. Garner,et al.  A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. , 2009, British journal of clinical pharmacology.

[24]  K. Maeda,et al.  Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine , 2008, Molecular Pharmacology.

[25]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  Malcolm Rowland,et al.  Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs , 2006, Clinical pharmacology and therapeutics.

[27]  D. Mayers,et al.  Microdose Pharmacokinetics of IDX899 and IDX989, Candidate HIV‐1 Non‐Nucleoside Reverse Transcriptase Inhibitors, Following Oral and Intravenous Administration in Healthy Male Subjects , 2009, Journal of clinical pharmacology.

[28]  G R Wilkinson,et al.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[29]  Akihiro Hisaka,et al.  Theoretical considerations on quantitative prediction of drug-drug interactions. , 2010, Drug metabolism and pharmacokinetics.

[30]  K. Maeda,et al.  INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID , 2006, Drug Metabolism and Disposition.

[31]  Shufeng Zhou,et al.  Polymorphism of human cytochrome P450 enzymes and its clinical impact , 2009, Drug metabolism reviews.

[32]  Yuichi Sugiyama,et al.  Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.